Lake Street Capital Markets downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold with a price target of $16.00 (from $30.00). Analysts expects slower than expected growth in commercial insurance coverage as a result of USPSTF draft guidance on colorectal cancer screening.

For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.

Shares of Exact Sciences closed at $18.53 yesterday.

Analyst PT Change Downgrades

Exact Sciences (EXAS) Drops Another 20%October 8, 2015 11:25 AM Whitney Tilson Says Exact Sciences (EXAS) Still a Great ShortOctober 7, 2015 10:20 AM Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines October 7, 2015 6:50 AM Exact Sciences (EXAS) PT Lowered to $15 at Roth Capital, Recommends Buying on WeaknessOctober 6, 2015 12:14 PM Exact Sciences (EXAS) PT Slashed to $11 at Goldman Sachs on Negative USPSTF RulingOctober 6, 2015 9:32 AM Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines October 6, 2015 8:45 AM Benchmark Downgrades Exact Sciences (EXAS) to HoldOctober 6, 2015 8:03 AM USPSTF Draft Recommendation Not as Bullish as Expected for Exact Sciences (EXAS), Wedbush Says; But Would Buy Below $18October 6, 2015 7:25 AM Impact on Exact Sciences (EXAS) from USPSTF Guidlines 'Unclear', Jefferies Says; Would Be Buyers on WeaknessOctober 6, 2015 6:53 AM Exact Sciences (EXAS) Issues Statement on USPSTF Colorectal Cancer Screening Draft RecommendationOctober 6, 2015 6:29 AM After Hours Stocks Movers 10/05: (STRZA) (RGLS) (LGF) Higher; (EXAS) (ILMN) (TCS) (more...)October 5, 2015 6:33 PM Exact Sciences (EXAS) Shares Drop After-HoursOctober 5, 2015 5:45 PM